(Q39703281)

English

An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20473889%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20473889%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

toll-like receptor

0 references

evasion of host immune response

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20473889%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

12

object named as

Stefan Endres

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20473889%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Collin Jacobs

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20473889%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Klaus Heckelsmiller

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20473889%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Jiwu Wei

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20473889%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Franz Bauernfeind

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20473889%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Jonathan Ellermeier

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20473889%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Ulrich Kisser

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20473889%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Christian A Bauer

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20473889%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Marc Dauer

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20473889%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Andreas Eigler

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20473889%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Eugene Maraskovsky

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20473889%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Max Schnurr

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20473889%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

language of work or name

0 references

publication date

1 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20473889%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20473889%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

128

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20473889%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20473889%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

897-907

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20473889%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25399

21 January 2018

High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25399

21 January 2018

Immunosuppressive strategies that are mediated by tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25399

21 January 2018

Regulatory T cells in the past and for the future

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25399

21 January 2018

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25399

21 January 2018

Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25399

21 January 2018

Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25399

21 January 2018

Dendritic cells pulsed with alpha-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25399

21 January 2018

ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25399

21 January 2018

Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25399

21 January 2018

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25399

21 January 2018

Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25399

21 January 2018

Regulatory T cells and immune tolerance

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25399

21 January 2018

Development of TLR9 agonists for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25399

21 January 2018

NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25399

21 January 2018

Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25399

21 January 2018

Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25399

21 January 2018

Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25399

21 January 2018

Determinant spreading and tumor responses after peptide-based cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25399

21 January 2018

Survivin expression and its clinical significance in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25399

21 January 2018

Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25399

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39703281&oldid=2089016052"